Tumour-associated macrophages (TAMs) are enriched in glioblastoma multiformes (GBMs) that contain glioma stem cells (GSCs) at the apex of their cellular hierarchy. The correlation between TAM density and glioma grade suggests a supportive role for TAMs in tumour progression. Here we interrogated the molecular link between GSCs and TAM recruitment in GBMs and demonstrated that GSCs secrete periostin (POSTN) to recruit TAMs. TAM density correlates with POSTN levels in human GBMs. Silencing POSTN in GSCs markedly reduced TAM density, inhibited tumour growth, and increased survival of mice bearing GSC-derived xenografts. We found that TAMs in GBMs are not brain-resident microglia, but mainly monocyte-derived macrophages from peripheral blood. Disrupting POSTN specifically attenuated the tumour-supportive M2 type of TAMs in xenografts. POSTN recruits TAMs through the integrin α v β 3 as blocking this signalling by an RGD peptide inhibited TAM recruitment. Our findings highlight the possibility of improving GBM treatment by targeting POSTN-mediated TAM recruitment.
GBM is the most common and lethal type of primary brain tumour 1 . The median survival of GBM patients is less than 16 months despite optimal treatment 2 . Abundant macrophage infiltration is a common feature of GBMs, but these TAMs in GBMs lack apparent phagocytic activity 3 . In addition, an inverse correlation between TAM infiltration and GBM prognosis has been reported 4 . Recent studies suggested that TAMs may promote GBM tumour progression in multiple aspects [5] [6] [7] [8] . The TAM-secreted cytokines, including IL-6 and IL-10, have been shown to promote cancer cell proliferation in GBMs (ref. 8) . TAMs could also facilitate GBM tumour growth by promoting neo-vascularization 6, 7 . Moreover, TAMs can interfere with the anti-tumour functions of other immune cells 5 , although TAMs do not exhibit traditional immunocyte properties. Thus, TAMs mainly play a tumour-supportive role in GBM progression. As pioneering immunotherapies have shown initial promise for GBM treatment, interrogating immunologic regulation in GBMs may inform therapy [9] [10] [11] . In addition, as TAMs in GBM may originate from either monocytes from peripheral blood or resident microglia in brain, identifying the source of TAMs in GBMs will provide critical information to determine the appropriate therapeutic approaches.
Therefore, determining the cellular and molecular mechanisms underlying TAM recruitment may facilitate the development of therapeutics to effectively improve GBM treatment.
Macrophages can be categorized into M1 and M2 subtypes based on their polarization status 12 . In tumours, the M1 or M2 subtype TAMs represent tumour-suppressive or tumour-supportive macrophages, respectively 13 . Cell surface markers including Iba1 and CD11b are commonly used to label total TAMs (refs 12,14) . Several surface markers such as CD163, Fizz1 and Arg1 have been used to mark M2 subtype TAMs, whereas other surface markers including MHCII, CD11c and iNOS have been suggested for M1 subtype TAMs (refs 15-19) . Although TAMs in lower grade astrocytomas were strongly stained with the M1 marker MHCII (ref. 20) , TAMs in GBM tumours manifested strong M2 marker staining 15, 21 . Such correlation between tumour grades and the M2 TAM abundance further suggests that the M2 type TAMs might play a critical role in GBM progression. However, TAMs in GBMs may be derived from circulating monocytes or resident microglia 13, 16 . Despite the fact that these two populations may share some surface markers in brain 17, 18 , studies using CX3CR1(+/GFP)/CCR2(+/RFP) knock-in Figure 1 POSTN is preferentially secreted by GSCs and its levels correlate with TAM density in GBMs. (a) Immunofluorescent staining of POSTN (green) and the GSC marker OLIG2 or SOX2 (red) in human primary GBMs. Frozen sections of GBMs (CCF2445 and CW672) were immunostained with antibodies against POSTN and SOX2 or OLIG2, and counterstained with DAPI to show nuclei (blue). POSTN was preferentially expressed in GSCs and distributed in the area near GSCs. Scale bars, 20 µm. (b) Graphical analysis of a showing the fraction of POSTN + cells in SOX2 + cells (GSCs) in human primary GBMs. More than 70% of SOX2 + GSCs showed POSTN staining (n = 5 GBMs; mean ± s.e.m.). (c,d) Immunoblot analysis of POSTN expression in cell lysates (c) and conditioned media (d) from GSCs (+) and matched NSTCs (−). Conditioned media were obtained by culturing equal numbers of GSCs and NSTCs in neurobasal media without supplements for 24 h and concentrating media by vacuum centrifugation. Endogenous tubulin amounts in the corresponding cells were used for control. (e) Immunofluorescent analysis of POSTN (red) and the TAM marker Iba1 (green) in GBM tissue microarray (US Biomax). Two sets of representative staining are presented to show the enrichment of TAMs in POSTN-abundant regions in GBMs. Areas indicated with squares are enlarged and shown on the right side of each picture. Scale bars, 80 µm. (f) Immunohistochemical staining of POSTN and the TAM marker Iba1 in two consecutive tissue microarray slides, respectively. Representative staining images show that the GBM (GL803a C6) with higher POSTN (POSTN H ) levels contained more Iba1+ (Ib1 H ) cells (TAMs) and the GBM (GL803a E7) with lower POSTN (POSTN L ) levels has fewer Iba1 + (Iba1 L ) cells (TAMs). Scale bars, 40 µm. (g) Graphical analysis of POSTN and Iba1 staining in the tissue microarray slides. 52.5% of GBM cases showed POSTN H and Iba1 H staining, and 28.75% of GBM cases showed POSTN L and Iba1 L staining. Only 12.5% of GBM cases showed POSTN H but Iba1 L staining, and 6.25% of GBM cases showed POSTN L but Iba1 H staining. Most (81.25%) GBM cases showed that POSTN levels positively correlate with TAM density. (Data from 80 tumours.) Uncropped images of blots are shown in Supplementary Fig. 9 . fluorescent protein reporter mice demonstrated that microglia are CX3CR1 + /CCR2 − but the monocyte-derived macrophages are CCR2 + /CX3CR1 − (ref. 22) , indicating that microglia and monocytederived macrophages in brains are different populations with distinct and specific surface antigens.
GBM exhibits a remarkable cellular heterogeneity and differentiation hierarchy. GSCs at the apex of this hierarchy are able to self-renew, differentiate and repopulate the whole tumour bulk [23] [24] [25] . GSCs contribute to GBM tumour growth, vascularization and therapeutic resistance 26, 27 . GSCs are localized and maintained in specific microenvironments called niches within a GBM tumour. Surprisingly, the GSC niches are also enriched with TAMs (refs [28] [29] [30] . Both TAMs and GSCs are abundant in the proximity of blood vessels known as the perivascular niche 28, 31, 32 . In the hypoxic regions within GBM tumours, a high density of CD11b + and F4/80 + TAMs can be detected 29, 30, 33 . Consistently, several lines of evidence highlighted the enhanced propagation of GSCs in the hypoxic regions 30, 33 . Furthermore, similar to the concurrence between the increased GSC population and GBM relapse 19, 34 , correlation between TAM re-infiltration and tumour recurrence is often detected in GBMs (ref. 35 ). These phenomena strongly suggest an interrelationship between GSCs and TAMs in GBM tumours.
To interrogate the molecular link between GSCs and TAM recruitment, we screened for candidate chemoattractants of TAMs from GSC-secreted proteins. We identified POSTN as a potent TAM attractant that is preferentially expressed in GSCs. POSTN (originally called OSF-2) is a member of the Fasciclin family and a disulphide-linked cell adhesion protein 36 . POSTN is involved in various aspects of tumorigenic processes through signalling pathways such as Akt/PI(3)K, integrin and Wnt-1 (refs 37,38) . Recently, POSTN was shown to be preferentially upregulated in stromal fibroblasts of breast cancer and help the maintenance of breast cancer stem cells by increasing Wnt signalling; thus, POSTN plays a supportive role in cancer stem cell metastatic colonization and breast cancer metastasis 38 . In addition, POSTN plays crucial roles to promote tumour progression including growth, invasion and metastasis in several malignant cancers 36, 38, 39 . In this study, we found that TAM density positively correlates with POSTN protein levels in human GBMs. Disrupting POSTN markedly reduced TAM density, inhibited tumour growth and increased the survival of mice bearing the GSC-derived xenografts. We determined that TAMs in GBMs are mainly monocyte-derived macrophages (CCR2 + /CX3CR1 − ) from peripheral blood but not resident microglia (CX3CR1 + /CCR2 − ) from brain. Silencing POSTN specifically attenuated the tumour-supportive M2 type (CD163 + /Fizzl + ) of TAMs in GSC-derived tumours. We further demonstrated that POSTN mediates through the integrin α v β 3 to recruit TAMs in vivo. Thus, POSTN secreted by GSCs recruits M2 type TAMs to support GBM growth.
RESULTS

POSTN is preferentially secreted by GSCs and correlates with TAM density in primary GBMs
To investigate the potential molecular link between GSCs and TAM recruitment, we screened for GSC-secreted specific factors that can potently attract macrophages (primed U937) in in vitro migration and invasion assays. First, we determined several secreted factors differentially expressed by GSCs through analysis by quantitative PCR with reverse transcription (RT-qPCR) and identified POSTN as one of the most abundantly expressed factors in GSCs (Supplementary Table 1 ). The Transwell migration and invasion assays indicated that POSTN is a dominant chemoattractant to attract the primed U937 macrophage-like cells ( Supplementary Fig. 1a,b ). Bioinformatic analyses of the TCGA database showed that POSTN expression negatively correlates with overall and progression-free survival of GBM patients ( Supplementary Fig. 1c,d) . To interrogate the potential link between POSTN expression and GBM tumour growth, we examined the pattern of POSTN expression in human GBM surgical specimens by immunofluorescence and found that POSTN is preferentially expressed by cancer cells expressing GSC markers (SOX2 and OLIG2) and distributed in the area around GSCs (Fig. 1a,b and Supplementary Fig. 1e ). To confirm the differential expression of POSTN in GSCs, we measured POSTN protein levels in matched GSCs and non-stem tumour cells (NSTCs) and found that GSCs preferentially expressed much higher levels of POSTN relative to NSTCs (Fig. 1c ). Consistently, conditioned medium from GSCs contains much more POSTN protein than that from matched NSTCs (Fig. 1d ). These data demonstrate that POSTN is preferentially secreted by GSCs in human GBMs. As GSCs and TAMs are both enriched in perivascular niches in GBMs, we next examined the potential link between POSTN expression and TAM density in primary GBMs in tissue microarrays. Immunofluorescence with antibodies against POSTN and the macrophage marker Iba1 confirmed that TAMs are enriched in POSTN-abundant regions ( Fig. 1e and Supplementary Fig. 1f ,g). Immunohistochemistry confirmed that GBMs with higher levels of POSTN contain a higher density of TAMs ( Fig. 1f,g ), suggesting a positive correlation between POSTN expression levels and TAM density in human GBMs.
Silencing POSTN in GSCs reduces TAM recruitment, inhibits tumour growth and extends survival of mice bearing GSC-derived xenografts
To address whether GSC-secreted POSTN plays a role in TAM recruitment and GBM tumour growth, we examined the effect of POSTN knockdown on TAM density and tumour growth in GSC-derived GBM xenografts. Lentiviral-mediated short hairpin RNA (shRNA) silencing reduced POSTN expression in GSCs by 85-90% ( Fig. 2a and Supplementary Fig. 2a ). GSCs expressing POSTN shRNAs or non-targeting shRNA and firefly luciferase were transplanted into immunocompromised mice through intracranial injection. Bioluminescent imaging of orthotopic tumours in vivo showed a marked inhibition of tumour growth in the xenografts derived from GSCs expressing POSTN shRNA relative to those expressing non-targeting shRNA ( Fig. 2b ). Consistently, silencing POSTN also significantly extended the survival of mice bearing the GSC-derived tumours ( Fig. 2c and Supplementary Fig. 2b,c) . These data demonstrate a supportive role for POSTN in GBM tumour growth. Given that POSTN protein levels showed a positive correlation with TAM density in primary GBMs, we next examined the impact of POSTN downregulation on TAM density in GSC-derived xenografts with immunofluorescence staining of two well-defined macrophage Targeting POSTN by two distinct shRNA clones O56 and O57 through lentiviral infection reduced POSTN expression by 85-90% in GSCs (T387). (b) In vivo bioluminescent imaging analysis of tumour growth in mice bearing GBM xenografts derived from GSCs expressing non-targeting shRNA or POSTN shRNA. GSCs (T387) were transduced with firefly luciferase and POSTN shRNA or non-targeting shRNA and then engrafted intracranially into athymic nude mice. Representative images on day 15 post transplantation are shown (data from 5 mice). Silencing POSTN by both O56 and O57 shRNA clones markedly delayed tumour growth. (c) Kaplan-Meier survival curves of mice implanted with GSCs expressing POSTN shRNA or non-targeting shRNA (control). GSCs were transduced with POSTN shRNA (O56 or O57) or non-targeting shRNA through lentiviral infection and then were transplanted intracranially into athymic nude mice (20,000 cells per mouse). Survival curves were analysed by two-tailed log-rank test. Mice bearing GSC-derived tumours expressing POSTN shRNA showed a significant survival extension relative to the control group. * * * , P < 0.001 (n = 6 mice for non-targeting shRNA and O57, and n = 8 mice for O56). (d) Immunofluorescent analysis of POSTN (red) and the TAM marker Iba1 (green) in GBM tumours derived from GSCs expressing POSTN shRNA or non-targeting shRNA. Frozen sections of GBM tumours derived from GSCs with POSTN shRNA (O56 and O57) or nontargeting shRNA were immunostained with antibodies against POSTN and Iba1 and counterstained with DAPI (blue). Marked reductions of POSTN and Iba1 (TAMs) signals were detected in the GSC-derived tumours expressing POSTN shRNA. Scale bars, 80 µm. (e,f) Graphical analyses of d showing a decrease of POSTN signal intensity by ∼80% and a significant reduction of TAM density by ∼60% in the GSC-derived tumours expressing POSTN shRNA. POSTN intensity and TAM density were analysed with ImageJ. * , P < 0.05; * * * , P < 0.001 (n = 5 tumours; mean ± s.e.m.; two-tailed unpaired t-test). Uncropped images of blots are shown in Supplementary Fig. 9 .
makers Iba1 and CD11b (refs 40,41) . TAM density was markedly reduced by more than 65% in the tumours derived from GSCs expressing POSTN shRNA whereas abundant TAMs were present in control tumours derived from GSCs transduced with non-targeting shRNA ( Fig. 2d-f and Supplementary Figs 2d ,e and 3a-c). We confirmed that Iba1 and CD11b staining overlapped in marking (the marker for monocyte-derived macrophages) and CX3CR1 (the microglia marker) in GBM xenograft and normal brain tissue. Frozen sections of GSC-derived tumour (T387) and the adjacent normal mouse brain were immunostained with antibodies against CCR2 (green) and CX3CR1 (red) and counterstained with DAPI (blue). CCR2 + cells were detected only in tumour tissue, whereas CX3CR1 + cells were detected only in normal brain. Scale bars, 40 µm. (b) Immunohistochemical staining of CCR2 and CX3CR1 in human primary GBMs and normal brain tissue. Two consecutive tissue microarray slides (US Biomax) containing GBMs and normal brain tissues were immunostained with antibody against CCR2 or CX3CR1 (brown) and counterstained with haematoxylin. GBM tumours showed abundant CCR2 + cells (the monocyte-derived TAMs) but not CX3CR1 + cells (microglia), whereas normal brain tissues contained CX3CR1 + cells but not CCR2 + cells. Scale bars, 40 µm. (c) Graphical analysis of b in tissue microarrays showed that CCR2 + cells (monocyte-derived TAMs) were detected in most (82.6%) GBM cases (data from 23 tumours) and a minority (20%) of normal brains (data from 5 normal samples). In contrast, CX3CR1 + cells (microglia) were detected in all normal brains but only 4.3% of GBM tumour cases. (d) Immunofluorescent staining of Iba1 and CD31 in human primary GBMs. Frozen sections of a primary GBM (CCF2445) were immunostained with antibodies against Iba1 to label TAMs (green) and CD31 to mark vessels (red) and counterstained with DAPI (blue). Abundant TAMs are enriched in perivascular niches. Scale bars, 80 µm. (e) Immunofluorescent staining of the TAM marker Iba1 and the endothelial marker Glut1 in GSC-derived xenografts. Frozen sections of GBM xenografts derived from GSCs (T387) were immunostained with antibodies against Iba1 (green) and Glut1 (red) and counterstained with DAPI (blue). TAMs (green) were localized near vessels but not in areas lacking blood vessels. Scale bars, 80 µm. Fig. 3d ) and the isolated TAMs from the subcutaneous xenografts ( Supplementary  Fig. 3e ). Collectively, these data demonstrate that GSC-secreted POSTN plays critical roles in promoting TAM recruitment and GBM tumour growth.
TAMs in GBM intracranial xenografts (Supplementary
TAMs in GBM are monocyte-derived macrophages from peripheral blood As the origin of TAMs in GBM has not been well defined, we next sought to address whether TAMs recruited by POSTN in GBM tumours are monocyte-derived macrophages from peripheral (n = 5 fields; mean ± s.e.m.; two-tailed unpaired t-test). All Transwell assays were repeated three times. Uncropped images of blots are shown in Supplementary Fig. 9 . blood or resident microglia from brain. Previous reports have shown that microglia within normal brain are CX3CR1 + /CCR2 − whereas the monocyte-derived macrophages are CCR2 + /CX3CR1 − (refs 22, 42), so we applied these markers to analyse the TAMs in GSCderived xenografts and primary GBM tumours. Consistently, most macrophages were CX3CR1 + /CCR2 − within the normal mouse brain (Fig. 3a, bottom panels) , confirming they were resident microglia. However, only CCR2 + /CX3CR1 − macrophages were found in the GSC-derived GBM xenografts (Fig. 3a, top panels) , demonstrating that POSTN-recruited TAMs in GBMs were monocyte-derived macrophages from peripheral blood. We further validated that TAMs in most human primary GBMs were also CCR2 + /CX3CR1 − , the monocyte-derived macrophages (Fig. 3b,c and Supplementary   Fig. 4a ). Moreover, we found that TAMs were enriched around blood vessels in primary GBMs and the GSC-derived xenografts (Fig. 3d,e ). These data demonstrate that the recruited TAMs in GBMs are mainly monocyte-derived macrophages originated from peripheral blood.
Disrupting POSTN in GSCs specifically reduces M2 tumour-supportive TAMs in vivo
Recent studies indicated that there are at least two subtypes (M1 and M2) of TAMs in tumours [43] [44] [45] . The M1 subtype has an inhibitory effect on tumour growth whereas the M2 subtype plays a supportive role to promote tumour progression by secreting cell growth cytokines and survival factors [46] [47] [48] . To address which subtype of TAMs was recruited or maintained by POSTN in GBM tumours, we applied M2-specific markers (Fizz-1, CD163 and Arg1) 15, 49, 50 and M1-specific markers (MHCII and CD11c) 14, 51 to distinguish TAMs in GSC-derived tumours. More than 50% of TAMs in control tumours derived from GSCs expressing non-targeting shRNA were M2 subtype TAMs as they were positive for Fizz-1, CD163 and Arg1 (Fig. 4a-i) , which mimics the situation in primary GBMs ( Supplementary Fig. 4b-g ). However, the M2 TAMs (Fizz-1 + , CD163 + or Arg1 + ) were markedly reduced in the GBM tumours derived from GSCs expressing POSTN shRNA ( Fig. 4a-i) , indicating that disrupting POSTN in GSCs attenuated the M2 TAMs in the GSC-derived tumours. Consistently, overexpression of POSTN in GSCs accelerated xenograft growth and increased M2 TAM recruitment (Fig. 4j,k) . In addition, a fraction (<50%) of TAMs was positive for the M1 subtype markers MHCII and CD11c in tumours derived from GSCs transduced with non-targeting shRNA ( Fig. 5a-f ). In contrast, most TAMs in the GBM tumours derived from GSCs expressing POSTN shRNA showed positive staining for the M1 markers MHCII and CD11c (Fig. 5a-f ), although total TAMs were markedly reduced in the POSTN-silencing tumours relative to POSTN-expressing tumours. In addition, F4/80, a marker for macrophage maturation 52 , was detected in most TAMs (76% ∼ 88%) within POSTN-silencing tumours ( Fig. 5g-i) . However, only a small proportion (10-15%) of TAMs in the tumours derived from GSCs transduced with non-targeting shRNA were F4/80 positive ( Fig. 5g-i ), suggesting an inhibition of macrophage maturation by POSTN in GBM tumours. Collectively, these data indicate that GSC-secreted POSTN also plays a critical role in maintaining the M2 subtype of TAMs in GBM tumours.
To further validate the role of POSTN in regulating the M1/M2 subtype of TAMs, we applied qPCR to determine the expression of multiple M2 and M1 markers in TAMs. CD11b + cells in GBM xenografts were isolated by magnetic-assisted cell sorting. When we examined M1/M2 marker expression in the CD11b + populations from xenografts derived from GSCs expressing nontargeting shRNA or POSTN-shRNA-expressing GSCs, we detected a significant downregulation of the M2 markers STAB1 and Lyve1 but a substantial upregulation of the M1-specific markers CCL17 and IL1b (ref. 43) in the CD11b + TAMs isolated from the xenografts derived from POSTN-silencing GSCs (Fig. 5j ). These data further confirmed that POSTN not only recruits TAMs but also maintains the M2 subtype of TAMs in GBMs.
POSTN exhibits a potent capacity to recruit macrophages/monocytes
To validate whether POSTN functions as a potent GSC-secreted chemoattractant, we performed a series of migration and invasion assays to examine the capacity of POSTN to attract macrophages/monocytes. Conditioned media from GSCs attracted significantly more PMA-primed macrophage-like U937 cells than the media from matched NSTCs (Fig. 6a,b ). Pre-incubation of GSCconditioned media with an anti-POSTN antibody attenuated the promoting effect of macrophage migration (Fig. 6c,d ). Furthermore, silencing POSTN expression in GSCs by two specific shRNAs also significantly reduced this chemoattractant effect (Fig. 6e,f) . When exogenous POSTN was overexpressed in NSTCs (Fig. 6g) , the resultant conditioned media exhibited a markedly increased ability to attract the U937-derived macrophage-like cells (Fig. 6h,i) .
The capacity of POSTN to attract monocyte/macrophages was further demonstrated with the isolated human primary monocytes in migration and invasion assays ( Fig. 6j-m) . To further address whether the POSTN-mediated attractant effect is dose dependent, we examined the impact of different concentrations of recombinant POSTN (rPOSTN) protein on macrophage migration. The migration of U937 macrophages towards POSTN was significantly enhanced with an increase of rPOSTN protein (Fig. 6n,o) , indicating that POSTN attracts macrophages in a dose-dependent manner. Collectively, these data demonstrate that POSTN preferentially secreted by GSCs exhibits a potent capacity to attract macrophages.
POSTN recruits TAMs through integrin α v β 3 signalling
Next, we turned attention to the molecular mechanisms underlying the POSTN-mediated recruitment of TAMs. Previous reports suggested that the integrin α v β 3 is the key receptor for POSTN in mediating cell migration 53, 54 . Immunofluorescence staining showed that TAMs in GBM xenografts and primary GBM tumours express the integrin α v β 3 (Fig. 7a,b ), suggesting that the POSTN-integrin α v β 3 axis may regulate TAM recruitment. To elucidate the signalling mediated by POSTN for TAM recruitment, we examined whether GSC-secreted POSTN can activate the integrin α v β 3 on monocyte-derived macrophages in vitro. We applied the U937 line that can be primed from monocytes to macrophage-like cells 55, 56 for the study, as most of the PMA-primed U937 cells are integrin α v β 3 positive (Fig. 7c ). Consistently, POSTN induced activation of Akt in the primed U937 cells, which can be blocked by addition of anti-integrin α v β 3 antibody (Fig. 7d) , indicating that POSTN can activate the integrin α v β 3 pathway in macrophages. We then examined the impact of an integrin inhibitory RGD peptide (Arg-Gly-Asp-d-Phe-Lys) related to a clinically developed anti-tumour agent, Cilengitide 57 , on POSTN-mediated recruitment of U937 macrophages. Disruption of the integrin signalling in U937 cells by the RGD inhibitory peptide significantly attenuated the recruitment of the macrophages by rPOSTN protein (Fig. 7e,f ), suggesting that the integrin α v β 3 on the macrophage surface is involved in the response to POSTN. To confirm whether the POSTNintegrin α v β 3 axis plays a critical role in POSTN-mediated TAM recruitment in vivo, we further investigated the inhibitory effect on TAM recruitment by the RGD peptide in GSC-derived GBM xenografts. Surprisingly, the GSC-derived tumours in the group of mice treated with the RGD peptide for 5 days showed an ∼70% reduction in TAM density relative to the control tumours from mice treated with a control peptide (Fig. 7g,h) . Taken together, these data indicate that POSTN recruits TAMs through integrin α v β 3 signalling in GBM tumours.
Intracranial co-transplantation of M2 subtype TAMs with GSCs accelerates tumour growth of GSC-derived xenografts
As silencing POSTN specifically reduces M2 type TAMs and potently inhibited tumour growth in GSC-derived xenografts, we next investigated the role of M2 TAMs in GBM tumour growth. Statistical analysis of the TCGA database showed that the M2 macrophage marker CD163 negatively correlated to GBM patient survival ( Supplementary Fig. 4h ), but the M1 macrophage marker MHCII positively correlated to prognosis ( Supplementary Fig. 4i ). In addition, immunofluorescent and immunohistochemical analyses Integrin Supplementary  Fig. 9 .
demonstrated a positive correlation between POSTN expression and M2 subtype macrophage density in human GBM specimens ( Supplementary Fig. 5a-c) . POSTN treatment enhanced expression of M2 markers but reduced expression of M1 markers in mouse intraperitoneal macrophages and U937-derived macrophage-like cells ( Supplementary Fig. 5d,e ), although disrupting POSTN by shRNAs showed a mild impact on GSC proliferation in vitro ( Supplementary  Fig. 6a-c) . These data suggest that the M2 subtype TAMs recruited and maintained by GSC-secreted POSTN may play a critical role in GSC-derived xenograft growth. To further explore the impact of M2 subtype TAMs on GBM tumour growth, we isolated CD11b + TAMs that are enriched with M2 subtype TAMs from GSCderived orthotopic xenografts, and then transplanted these TAMs with luciferase-expressing GSCs into mouse brains. Bioluminescent imaging demonstrated that intracranial co-transplantation of M2 TAMs with GSCs markedly accelerated GSC tumour growth relative to the transplantation of GSCs alone (Fig. 8a) . Moreover, cotransplantation of M2 TAMs with GSCs also significantly shortened the survival of animals relative to the GSC transplantation alone (Fig. 8b ). In addition, co-transplantation of M2 TAMs with GSCs expressing POSTN shRNA partially rescued the inhibition of GSC tumour growth caused by POSTN disruption (Fig. 8c) , indicating an essential role for TAMs in mediating the POSTN-promoted tumour growth. The failure to fully rescue the inhibiting effect of POSTN silencing in GSC tumour growth by the co-transplanted M2 TAMs may be ascribed to the loss of M2 properties, impacted viability, or migration away of these TAMs from the tumour due to the absence of POSTN. Collectively, these data demonstrate that the M2 subtype TAMs have a potent capacity to promote GBM growth in vivo.
DISCUSSION
GBM often contains a large number of TAMs that constitute the dominant immune cell population within the tumour. Accumulating evidence suggests that TAMs rarely phagocytize cancer cells or behave like antigen-presenting cells 43, 58 . M2 subtype TAMs are now widely regarded as immunosuppressive cells with a tumour-supportive role 15, 43 , although a role for M1 TAMs in anti-tumour immune responses has been reported 59 . Tumours may recruit TAMs through secretion of CC chemokine ligand 2 (CCL2) and soluble colonystimulating factor 1 (sCSF1) in other cancers [60] [61] [62] [63] . In this study, we demonstrated that TAMs in GBMs are mainly recruited by POSTN, a protein preferentially expressed by GSCs but rarely expressed by NSTCs or differentiated glioma cells in GBMs (Fig. 1c,d and Supplementary Fig. 6d-i) . GSC-secreted POSTN functions as a potent chemoattractant to recruit monocyte-derived macrophages from peripheral blood and maintain the M2 subtype of TAMs to promote tumour growth in GBMs (Fig. 8d ). The fact that only CCR2 + macrophages but not CX3CR1 + macrophages appeared in the GSC-derived GBM tumours indicates a preferential recruitment of peripheral macrophages by GSC-secreted POSTN, as CCR2 is a specific marker for monocyte-derived macrophages, whereas CX3CR1 is an indicator of resident microglia from brain 22, 42 . Consistently, we detected enrichment of TAMs around vessels (Fig. 3d,e ). As GSCs tend to cluster in perivascular niches 28, 31, 32 , GSCs may modulate their microenvironment through POSTN-mediated TAM recruitment to form a favourable niche for the survival of both GSCs and TAMs. The interplay between GSCs and TAMs may be critical to promote GBM tumour growth.
Our results demonstrated that disrupting POSTN in vivo significantly reduced recruitment of the tumour-supportive TAMs (M2 type) and inhibited GBM tumour growth. To determine other biological effects of POSTN downregulation in GBM tumours, we also examined the impact of targeting POSTN on several aspects of tumour biology such as vessel density, GSC population, cell proliferation and survival. POSTN knockdown had no obvious effects on vascular density in GSC-derived xenografts ( Supplementary  Fig. 7a-c) . Similarly, blocking POSTN-integrin α v β 3 signalling by RGD treatment did not have a significant impact on vessel density ( Supplementary Fig. 7d,e ). However, the vessel morphology changed to some degree, which may be associated with the reduced TAM density. In addition, POSTN knockdown had no significant impact on GSC populations in tumour bulk as demonstrated by SOX2 immunofluorescence ( Supplementary Fig. 8a,b ). Furthermore, there was no significant difference in cancer cell proliferation between the GSC-derived tumours expressing POSTN shRNA and nontargeting shRNA as indicated by Ki-67 staining ( Supplementary  Fig. 8c,d) . In contrast, targeting POSTN induced massive apoptosis in GSC-derived xenografts as demonstrated by TUNEL assay ( Supplementary Fig. 8e,f) . Moreover, qPCR analysis demonstrated a marked upregulation of M2 markers STAB1 and Lyve1 in CD11b + cells (TAMs) from GBM xenografts relative to resident microglias from normal mouse brains ( Supplementary Fig. 8g ). These data suggest that the reduced M2 TAMs caused by POSTN disruption might be closely associated with the increased apoptosis and inhibited tumour growth in the GBM xenografts expressing POSTN shRNA. Thus, POSTN-mediated recruitment and maintenance of M2 TAMs largely contributes to the accelerated tumour growth by promoting cancer cell survival in GBMs, although POSTN itself may also partially play a direct role in promoting tumour cell survival in vivo. It will be important to determine how POSTN-recruited M2 TAMs augment cancer cell survival in GBMs in future studies.
Our studies uncovered the cellular and molecular mechanisms underlying TAM recruitment in GBMs. We also identified the origin of TAMs and their subtype in this lethal type of brain tumour. GSCs preferentially secrete POSTN to recruit TAMs into GBM tumours, although other factors may also affect immune cells in GBMs. As POSTN-recruited TAMs are mainly monocyte-derived macrophages from blood, the contribution of microglia from brain to TAMs in GBMs is not as critical as we previously thought. Thus, targeting monocyte-derived TAMs should be considered as the main focus of GBM immunotherapy. Furthermore, we demonstrated that POSTNrecruited TAMs are maintained as the pro-tumorigenic M2 subtype of macrophages, indicating that the recruited TAMs may produce important factors to augment GBM tumour growth. Consistently, silencing POSTN expression markedly reduced TAMs and inhibited GBM tumour growth by reducing cell survival. As previous studies in other tumours such as colon cancers have shown that POSTN promotes cancer cell survival through AKT activation 36, 37 , it is likely that POSTN may affect GBM tumour growth through multiple mechanisms besides recruitment and maintenance of M2 TAMs. Thus, targeting POSTN signalling, blocking POSTN-mediated TAM recruitment and eliminating the POSTN producer GSCs are likely to be attractive therapeutic approaches. As a reciprocal supportive interplay between cancer cells and TAMs may be critical to promote tumour progression, disrupting the interrelationship between TAMs and cancer cells, especially GSCs, may effectively inhibit GBM tumour growth. Recently, targeting TAMs by trabectedin has been shown to exhibit a significant anti-tumour activity in lung carcinoma, ovarian cancer and fibrosarcoma 64 . Our finding of molecular mechanisms underlying TAM recruitment by GSC-secreted POSTN may shed light on the development of therapeutics to improve GBM treatment. In addition, therapeutic targeting of POSTN-mediated TAM recruitment may synergize with current immunotherapies to effectively increase the survival of patients with GBMs and possibly other lethal cancers.
METHODS
Methods and any associated references are available in the online version of the paper.
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M E T H O D S
METHODS
Human GBM specimens and glioma-derived cells. De-identified GBM surgical specimens were collected from Cleveland Clinic Brain Tumor and Neuro-Oncology Center and the University Hospitals Case Medical Center in accordance with Institutional Review Board-approved protocols. Informed consent was obtained from all patients. Tissue microarray slides containing 96 GBM samples were purchased from US Biomax. Characteristics of the original cancers were described previously 65 . GSCs and matched non-stem tumour (NSTCs) cells were isolated from GBM specimens or xenografts through cell sorting and functionally characterized as previously described 26, 27, 65, 66 with minor modification. Briefly, GBM tumours were disaggregated using the Papain Dissociation System (Worthington Biochemical) according to the manufacturer's instructions. Isolated cells were recovered in stem cell medium (Neurobasal-A medium with B27 supplement, 10 ng ml −1 EGF and 10 ng ml −1 bFGF) for at least 6 h to allow re-expression of surface markers, and then sorted by fluorescence-activated cell sorting (FACS) using at least two surface markers (CD15/CD133). Cells were labelled with a phycoerythrin (PE)-conjugated anti-CD133 antibody (Miltenyi Biotec, 130-098-826, 1:11) and the FITC-conjugated anti-CD15 antibody (Millipore, CBL144F, 1:20), and the CD133 + /CD15 + cells were isolated through cell sorting. The enriched GSCs (CD133 + /CD15 + ) were maintained in the stem cell medium and the identity was confirmed by SOX2 and OLIG2 expression and the activation of SOX2 promoter-driven GFP expression. The cancer stem cell phenotype of GSCs was validated by functional assays of selfrenewal (serial neurosphere formation at the clonal density), in vitro induction of differentiation and tumour propagation (in vivo limiting dilution assay) as previously described 26, 27, 65, 66 . After validation of the cancer stem cell phenotype by these functional assays, the sorted GSCs were used for the in vitro and in vivo experiments. The sorted CD133 − /CD15 − cells from matched GBM tumours were used as NSTCs.
Intracranial tumour formation in vivo. Intracranial transplantation of GSCs to establish GBM xenografts was performed as described previously 26, 65 . Female C57BL/6 athymic nude mice of 4-6 weeks were purchased from Charles River Laboratories. GSCs were transplanted into the right cerebral cortex at a depth of 3.5 mm through intracranial injection. Mice were euthanized when exhibiting neurological signs including domehead, haemiparesis, or more than 20% of body weight loss. All animal protocols were approved by the Animal Research Committee of the Cleveland Clinic, and all animals were housed in the Association for the Assessment and Accreditation of Laboratory Animal Care-accredited animal facility at Cleveland Clinic Lerner Research Institute. No specific method was used to predetermine sample size. The experiments were not randomized. Only animals with accidental death (for example, due to infection or intracranial injection) were excluded from the data analysis. The investigators were not blinded to allocation during experiments and outcome assessment. GSCs were transduced with expression of NT shRNA or POSTN shRNAs along with luciferase through lentiviral infection. Forty-eight hours after infection, 20,000 viable cells were engrafted intracranially into immunocompromised mice. Animals were monitored by bioluminescent imaging or maintained until manifestation of neurological signs.
Immunoblotting and immunofluorescent staining. Immunoblotting and immunofluorescent staining were performed as described previously 65, 67 . Specific antibodies against POSTN (Abcam, ab14041, 1:400), GSC markers SOX2 (Millipore, AB5603, 1:200; Santa Cruz, sc-17320, 1:200) or OLIG2 (R&D systems, AF2418, 1:100), endothelial cell markers Glut1 (Millipore, 07-1401, 1:500) or CD31 (Dako, M082301, 1:100), and macrophage markers Iba1 (Abcam, ab5076, 1:200), CD11b (Abd serotec, MCA711GT, 1:100), Fizz1 (Abcam, ab39626, 1:100), CD163 (Santa Cruz, sc-33560, 1:100), F4/80 (Abd serotec, MCA497RT, 1:100), CX3CR1 (Abcam, ab8021, 1:100) or CCR2 (Abcam, ab32144, 1:100) were used for immunofluorescent staining on GBM tumour sections as indicated. Specific antibodies against POSTN (Abcam, ab14041, 1:10,000), tubulin (Sigma, T8203, 1:10,000), phosphor-S473 Akt (Cell Signaling Technology, 9271, 1:1,000) and Akt (Cell Signaling Technology, 9272, 1:1,000) were used for immunoblot analyses. To determine TAM density, cryosections of GBM tumours were co-stained with Iba1 (or CD11b) and Glut1. The numbers of Iba1 + (or CD11b + ) cells were calculated by ImageJ. Glut1-positive areas were regarded as vessels and determined by ImageJ. For TAM density in each sample, the number of Iba1 + (or CD11 + ) cells was divided by vessel area for normalization to exclude individual variation in vascularization. The final outcome was defined as the TAM density.
Immunohistochemical staining. Immunohistochemical (IHC) staining was carried out with the ABC kit and the DAB kit (Vector Laboratories) according to the manufacturer's instructions. Primary antibodies against POSTN (ab14041, 1:400), Iba1 (ab5076, 1:400), CX3CR1 (ab8021, 1:100), CCR2 (ab32144, 1:100) and Ki-67 (ab15580, 1:400) from Abcam were used for the IHC staining. To study the correlation between POSTN level and TAM recruitment, sequential sections of primary GBM microarrays were stained with antibodies against POSTN or Iba1, respectively. The IHC staining of POSTN was evaluated by two independent pathologists. Samples with a score of 0-1 were regarded as low expression (POSTN L ) and those with a score of 2-3 were regarded as high expression (POSTN H ). For Iba1 evaluation, 3 random areas from a single section were checked for Iba1 + cells. If the average number of Iba1 + cells was less than 100 Iba1 + cells in 4.2 mm 2 (2.36 × 1.78 mm 2 ), the sample was ascribed to Iba1 low (Iba1 L ). Otherwise the sample was classified as Iba1 high (Iba1 H ). TUNEL assays. TUNEL assays detecting apoptosis in tumour sections were performed with an ApopTag Plus Peroxidase in situ apoptosis kit (Chemicon) according to the manufacturer's instructions.
U937 monocyte Transwell assays. U937 cells (ATCC) were cultured in the suggested medium 24 h before priming. U937 monocytes were primed with 5 nM PMA (Sigma) for 48 h to become monocyte-derived macrophages as described previously 55 . Transwell assays assessing cell migration or invasion potential were performed on 24-well plates with inserts (BD Biosciences) according to the manufacturer's instruction. Briefly, 5 × 10 5 primed U937 cells were cultured in the upper chamber and allowed to migrate or invade for 24-48 h before fixation for crystal purple staining. Recombinant human POSTN protein was purchased from R&D Systems. Conditioned media were obtained by culturing T387 GSCs or NSTCs in RPMI/1640 media with 0.1% BSA for 24 h and then used for the cell migration Transwell assay.
Isolation of human monocytes from blood. Human monocytes were isolated
by Ficoll-Paque PLUS (GE Healthcare) centrifugation of human blood followed by the collection of monocytes attached to the plastic surface after 4 h culture. Briefly, blood from donors was diluted in Hank's buffer to a 1:1 solution. The blood solution was placed over a half-volume of Ficoll-Paque PLUS (GE Healthcare) and centrifuged at 1,600 r.p.m. (515g ) for 30 min. The middle layer of PBMCs was collected and cultured in RPMI/1640 medium supplemented with 10% FBS. Four hours after culture, the floating cells were washed away with PBS. The adherent monocytes were trypsinized and subjected to migration or invasion assays. All studies related to human subjects were approved by the Institutional Review Board of the Cleveland Clinic. Informed consent was obtained from all subjects. For Transwell assays, 5 × 10 4 human monocytes/macrophages were cultured in the upper chamber and recombinant POSTN protein (0.5 µg ml −1 ) in RPMI/1640 media with 0.1% BSA was added in the lower chamber. Cells were allowed to migrate or invade for 24 h and the migrated cells in the bottom of the well were fixed and stained.
Isolation of CD11b + cells from GBM xenografts. Mouse brain tissues or GBM
xenografts were digested with the Neural Tissue Dissociation Kit (Miltenyi Biotec) followed by magnetic-assisted cell sorting with PE-conjugated anti-CD11b antibody (Miltenyi Biotec, 130-091-240, 1:11) and anti-PE-conjugated microbeads (Miltenyi Biotec). Briefly, mouse brains or tumours were washed with PBS, minced and incubated with enzyme mixes. The dissociated brain tissue was passed through a 40 µm cell strainer. Tissue was then re-suspended in a 30% Percoll (Santa Cruz) PBS solution and centrifuged at 700g for 10 min to remove myelin. Cells were resuspended in 90 µl IMAG buffer (PBS without Ca2+/Mg2+, supplemented with 0.5% BSA and 2 mM EDTA, pH 7.2) plus 10 µl anti-CD11b-PE (Miltenyi) and incubated on ice for 30 min. Cells were then washed three times with 1 ml IMAG buffer and incubated with 20 µl anti-PE microbeads (Miltenyi) plus 80 µl IMAG buffer on ice for 15 min. After labelling, cells were washed, re-suspended in 500 µl IMAG buffer, and applied to an MS column (Miltenyi). After washing 3 times, CD11b + cells were flushed out of the column by a plunger. CD11b + cells were then cultured in RPMI/1640 medium supplemented with 10% FBS for 1 h and used for co-injection or lysed for RNA extraction.
RGD peptide treatment in vivo.
After manifestation of clear luciferase signals in IVIS imaging, mice bearing GSC-derived xenografts were treated with RGD peptide (Peptides International, PCI-3661-PI) or control peptide (Peptides International, PCI-3883-PI) through intraperitoneal delivery. The peptides were dissolved in PBS at 5 mg ml −1 and mice were continuously treated with control or RGD peptide at 25 mg kg −1 for 5 days. Two hours after the last injection, mice were euthanized and brains were fixed in 4% PFA for analysis.
Isolation of mouse peritoneal macrophages. BALB/c mice of 6-8 weeks were stimulated by i.v. injection of 1 ml 3% Brewer thioglycollate medium into the peritoneal cavity. Inflammatory response was allowed for 4 days. Mice were then euthanized and the peritoneal macrophages were collected by washing the cavity with 1 ml ice cold PBS. DOI: 10.1038/ncb3090 shRNAs for knockdown. Lentiviral-mediated shRNAs targeting POSTN (TRCN0000123055 for O55; TRCN0000123056 for O56, and TRCN0000123057 for O57) or control shRNA (SHC002) were purchased from Sigma-Aldrich.
RT-qPCR of secreted proteins.
To identify potential chemoattractants differentially expressed by GSCs, we used RT-qPCR analysis to determine the expression of major secreted proteins, including most cytokines along with some secreted proteins relevant to tumorigenesis, in paired GSCs and NSTCs. qPCR primers were designed to span an intron of each target gene (Supplementary Table 1 ). Total mRNA was purified from paired GSCs and NSTCs with the RNeasy Mini Kit (74104, Qiagen). mRNA (500 ng) was reverse transcribed into cDNA with SuperScript III Reverse Transcriptase (18080-044, Invitrogen). RT-qPCR assays were performed with SYBR Green PCR Master Mix (4310251, Applied Biosystems) on a 7900HT thermal cycler (Applied Biosystems). Three-step amplification was performed (95 • C 15 s, 60 • C 15 s, and 72 • C 30 s) for 45 cycles. For data analysis, GAPDH was used as the internal standard and fold changes of gene expression levels in GSCs relative to NSTCs were calculated. The target genes with a > 2-fold upregulation in GSCs were regarded as differentially expressed. RT-qPCR was performed with 3 pairs of matched GSCs and NSTCs and repeated three times. Average fold changes of target genes presented were from 3 representative experiments.
Primers for other qPCR analyses. mSTAB1-qF: 5 -ACGGGAAACTGCTTG ATGTC-3 ; mSTAB1-qR: 5 -ACTCAGCGTCATGTTGTCCA-3 ; mLyve1-qF: 5 -CT GGCTGTTTGCTACGTGAA-3 ; mLyve1-qR: 5 -CATGAAACTTGCCTCGTGT G-3 ; mCcl17-qF:5 -AGTGCTGCCTGGATTACTTCAAAG-3 ; mCcl17-qR: 5 -CT GGACAGTCAGAAACACGATGG-3 ; mIL12a-qF: 5 -GGAAGCACGGCAGCA GAATA-3 ; mIL12a-qR: 5 -AACTTGAGGGAGAAGTAGGAATGG-3 ; mIL1b-qF: 5 -GTGTGGATCCAAAGCAATAC-3 ; mIL1bqR: 5 -GTCTGCTCATTCATGACA AG-3 ; mGAPDH-qF: 5 -TGATGACATCAAGAAGGTGGTGAAG-3 ; mGAPDH-qR: 5 -TCCTTGGAGGCCATGTAGGCCAT-3 .
Statistical analysis. The level of significance was determined by a two-tailed unpaired Student's t-test (bar graphs) or analysis of variance with α = 0.05 (survival curves) and analysed with GraphPad Prism 5 software. All quantitative data presented are the mean ± s.e.m. from at least three samples or experiments per data point.
Repeatability of experiments.
Representative Transwell images and the corresponding statistical analyses (Figs 6b-d,f,i,l,m,o and 7f and Supplementary  Fig. 1a,b ) are shown from three experiments. Immunofluorescent analyses (Figs 2e,f,  4b,c ,e,f,h,i,k, 5b,c,e,f,h,i and 7h and Supplementary Figs 2e, 3b,c, 7b ,c,e and 8b,d,f) are shown from three independent experiment using cryosections from 5 different xenografts. qPCR analyses ( Fig. 5j and Supplementary Figs 5d,e and 8g ) are shown from three independent experiments. Immunofluorescent analyses of human primary GBMs ( Fig. 1b and Supplementary Fig. 4e -g) are shown from 5 patients. Immunofluorescent analyses of human primary GBMs ( Supplementary Fig. 6e ,g,i) are shown from 3 patients. 
